Objectives: To assess the extent of immortal time bias in estimating the clinical effectiveness of implantable cardioverter-defibrillators (ICDs) and the impact of methods of handling immortal time bias.
Introduction
''Immortal time'' is the follow-up period during which, in some studies, the outcomes of interest cannot occur [1, 2] . For example, in observational studies of treatment effectiveness, immortal time can arise if the definition of treatment is made over time, that is, patients may receive delayed treatment within a certain period after cohort entry. The time between cohort entry and the date of treatment is immortal, meaning that these patients must survive until they receive the treatment. Either misclassifying this immortal time or omitting it from the analysis can bias the estimates in favor of the treatment being studied [3e6] and therefore affect the study's conclusions.
At least three approaches have been proposed to correct bias from immortal time. Mantel and Byar [7] first proposed that person-time should accrue to the various exposure states that patients occupy during treatment. It is also called time-dependent exposure assignment and is considered a gold standard method for handling immortal person-time bias. In the 1980s, Anderson et al. [8] proposed the landmark method for handling immortal time bias. Specifically, a fixed time after the initiation of therapy is selected as the landmark. Patients on study at the landmark time are classified into two exposure categories according to the patient's exposure status at the landmark, and are then followed from the landmark regardless of subsequent shifts in exposure status. Patients who die before the landmark time are excluded from the analysis. This approach effectively removes immortal time bias. However, the
What is new?
We compared ManteleByar, landmark, and exclusion methods of handling immortal time bias in a study of the clinical effectiveness of a medical device. We examined how the choice of time scale affects these methods.
Immortal time can bias the results and thus the inference when it is handled inappropriately.
Immortal time bias can be corrected by using appropriate design and statistical analyses, such as the ManteleByar method. Landmark is also a valid method when an appropriate landmark is selected.
The exclusion method is biased in favor of the treatment group and should be avoided. results may differ depending on the choice of the landmark. Exclusion of patients who die before the landmark time may lead to lower statistical power. A third and more controversial option is the exclusion method [1, 2, 8, 9] , in which immortal time is excluded from the analysis, patients who initiate therapy begin follow-up at initiation, and patients who never initiate therapy begin follow-up at cohort entry. Despite the recognition of available methods for handling immortal time bias, immortal time has frequently been mishandled in recently published observational studies of drug effects [5] .
Observational comparative effectiveness studies often use time to event as the outcome [3,4,6,10e16] . The choice of time origin and scale in these studies (hereafter time scale) can affect the composition of the risk sets and therefore the estimates of hazard ratios from Cox proportional hazards models [17, 18] . Although time on study is the most commonly used time scale, one previous study indicated that age may be the appropriate time scale [17] . Time on disease may also be appropriate because it is a predictor of outcomes and because some interventions, such as medical devices, can be used at different disease stages. The choice of time scale in study design also affects the validity of the method selected for handling immortal time in determining the underlying hazard function [2, 8] .
Little is known about the impact of various methods of handling immortal time bias and how the validity of these methods is affected by the choice of time scale in the context of comparative effectiveness studies of medical devices. Device therapies involve invasive, costly, and complicated procedures, and eligible patients may not receive them until their conditions become severe and/or other therapies fail. Therefore, assessing the effectiveness of a device therapy is subject to immortal time bias. A typical example is the implantable cardioverter-defibrillator (ICD), which is indicated for patients with heart failure (HF) to prevent sudden cardiac death and has been shown to be efficacious in clinical trials [19, 20] . We used data from a previous study of the clinical effectiveness of ICDs among Medicare beneficiaries with HF [11] to evaluate the extent of immortal time bias in comparative effectiveness studies of devices and to assess the impact of methods of handling immortal time bias and time scale. In this example, we hypothesized that the most appropriate method will yield hazard ratios similar to or higher than those from the trials, as the effectiveness of ICDs was expected to be attenuated in Medicare beneficiaries, who are older and have greater comorbidity than trial participants and are therefore more likely to die from causes other than sudden arrhythmic death.
Methods

Study population
The study data were from the American Heart Association's Get With the Guidelines-Heart Failure (GWTG-HF) registry and Medicare inpatient claims from the Centers for Medicare & Medicaid Services (CMS). Details of the design and objectives of the GWTG-HF registry have been described previously [21] . We linked the GWTG-HF registry to Medicare inpatient claims using the method described by Hammill et al. [22] . We used the same inclusion criteria as a previous study of the clinical effectiveness of ICDs [11] . The final data set included 5,226 eligible patients who were discharged home alive between January 1, 2003 and December 31, 2008 from 193 hospitals. The cohort entry was defined as the date of discharge from the index hospitalization, which was not necessarily the patient's first hospitalization for HF.
Measures
The outcome of interest was all-cause mortality during the 3 years of follow-up after the index hospitalization for HF. Dates of death were obtained from the CMS enrollment files. The treatment of interest was ICD therapy during the index hospitalization or during the 3 years of follow-up. We identified ICD procedures by searching for ICD-9-CM procedure codes 3794 and 0051 in the Medicare inpatient claims or as recorded in the registry. For each of the three methods of handling immortal time bias, we defined ICD status as follows (Fig. 1 ).
ManteleByar method
Patients were followed from the time of cohort entry. For patients who received ICD therapy, the time between cohort entry and the ICD implantation date was immortal (which we classified as non-ICD use), and the subsequent followup time was classified as the ICD follow-up period. We classified all other patients as non-ICD users. We used the counting process style of input, which allows multiple records per patient.
Landmark method
We selected 60 and 120 days after cohort entry as alternative landmark times. We classified patients as ICD users if they received ICD therapy before the landmark time and as non-ICD users otherwise, regardless of subsequent changes in ICD status. All patients were followed up from the landmark time instead of the index date. Patients who died or for whom data were censored before the landmark were excluded from the analysis.
Exclusion method
For patients who received ICD therapy, follow-up began on the date of ICD implantation and the immortal time before the implantation was excluded from the analysis. For patients who did not receive an ICD, follow-up began on the date of cohort entry.
We considered the following time scales, namely the time of cohort entry (i.e., time on study) and the time of the first HF hospitalization (a surrogate for time on disease or disease duration) ascertained from Medicare claims in the 3 years preceding the cohort entry, and time of birth (i.e., age).
Statistical analysis
We describe the patient characteristics by ICD status for the overall study population and for each analysis cohort derived from the three methods of handling immortal time bias. We present frequencies with percentages for categorical variables and means with standard deviations for continuous variables. We compared variables between treatment groups using c 2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables.
We compared person-years and mortality rates between the ICD group and the non-ICD group. We used Cox proportional hazards models to estimate the effect of ICD therapy on 3-year mortality. We compared three methods of handling immortal time bias and three time scales. To control for confounding, we used propensity scores (PSs) estimated using the high-dimensional PS (hd-PS) algorithm [23] , which is an automated technique that empirically identifies a large number of potential confounders or proxies for confounders in multiple longitudinal data sets. We estimated PSs separately for each immortal time bias method because both the sample size and the number of treated patients differed by method. We used inpatient diagnosis and procedure codes 3 years preceding the initiation date of the ICD therapy for the ICD group, and 3 years preceding cohort entry for the non-ICD group. Patient demographic characteristics were measured at the time of the ICD procedure for the ICD group and at the time of cohort entry for the non-ICD group. We fitted the following Cox proportional hazard models for each combination of the three methods of handling immortal time bias and three time scales, namely a model weighted by the inverse probability of treatment [24] , a model stratified on the quintiles of the hd-PS, and a regression adjusted for the hd-PS. We used robust standard errors to take into account the correlation of data within hospitals. We also calculated the adjusted risk difference in the Cox regression model [25] . All analyses were performed using SAS software version 9.1 (SAS Institute, Inc., Cary, NC).
Results
Of the 5,226 eligible patients, 650 (12.4%) received ICD therapy during the index hospitalization. Table 1 shows the baseline characteristics of the study population by ICD status at cohort entry. The ICD users were more likely to be younger (75.4 vs. 76.5 years), men (75.2% vs. 58.6%), and white (82.6% vs. 78.6%), to have ischemic HF (77.5% vs. 72.9%), to receive HF medications, and to have less comorbidity. An additional 624 (12%) patients received ICD therapy after the cohort entry. We created three analysis cohorts based on the methods of handling immortal time bias. From the Medicare claims, we obtained patient characteristics at cohort entry for non-ICD users and at treatment initiation for ICD users (Tables 1e3 in Appendix at www.jclinepi.com).
For the ManteleByar method, there were 2,639 total person-years in the ICD group, 490 more than for the exclusion method ( Table 2) . The difference reflects the amount of immortal time in the ICD group and suggests the potential impact of mishandling immortal time in the study.
Compared with the non-ICD group, the ICD group had lower mortality. Compared with the non-ICD group, the expected number of patients with a prevented event was 6, 8, 6, and 11 among 100 patients who received an ICD for ManteleByar, the 60-day landmark, the 120-day landmark, and exclusion methods, respectively.
The c-statistic for the hd-PS models was 0.77. As expected, there were considerable overlaps of the hd-PS for the ICD and non-ICD users (Fig. 1 in Appendix at www. jclinepi.com). We found extreme inverse probability weighting, which we trimmed in all analyses (Fig. 2 in Appendix at www.jclinepi.com). The hazard ratios for ICD effectiveness ranged from 0.66 (95% confidence interval [CI]: 0.58e0.77) to 0.89 (95% CI: 0.78e1.01) ( Table 3 ). When we used time on study as the time scale and the PS as a covariate in the outcome model to control for confounding, the ManteleByar method yielded the highest hazard ratio (0.84; 95% CI: 0.75e0.95), followed by the 120-day landmark method (0.82; 95% CI: 0.72e0.95), and the 60-day landmark method (0.78; 95% CI: 0.68e0.89). The exclusion method yielded the smallest hazard ratio (0.71; 95% CI: 0.63e0.80). The exclusion method yielded a hazard ratio approximately 16% lower than that of the ManteleByar method. Three time scales yielded similar hazard ratios for the estimates from the landmark and exclusion methods. In the ManteleByar analysis, estimates from different time scales varied; the estimates using time on study as the time scale were closer to the null than estimates from the other time scales (hazard ratio, 0.84; 95% CI: 0.75e0.95).
Discussion
We compared ManteleByar, landmark, and exclusion methods of handling immortal time bias and chose different time scales with which to measure the impact of immortal time bias and the effectiveness of different approaches. In a data set from a previous study assessing the clinical effectiveness of ICDs among Medicare beneficiaries, mishandling immortal time bias by the exclusion method resulted in up to 16% bias compared with the gold standard ManteleByar method. The landmark method tended to provide appropriate control for immortal time bias when a proper landmark time was selected.
Large randomized clinical trials have shown that ICDs provide survival benefits in patients with reduced left ventricular ejection fraction with HF or after myocardial infarction. The Multicenter Automatic Defibrillator Implantation Trial II reported a hazard ratio of 0.69 (95% CI: 0.51e0.93) [20] , and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) reported a hazard ratio of 0.77 (95% CI: 0.62e0.96) [19] . However, compared with cardiovascular clinical trial participants, Medicare beneficiaries are more likely to be older and women [26] . Older patients are more likely to have more comorbid conditions and therefore more competing causes of death [27] . Thus, results from clinical trials may not directly apply to the Medicare population [28] , and we expected a higher hazard ratio (O0.70) compared with that from the trials. Results from the ManteleByar method were the closest to what we expected.
The results of the landmark analyses varied depending on the choice of the landmark time. Hazard ratios in the 120-day landmark analysis were close to those from the ManteleByar method. Thus, although the 120-day landmark seems to be an appropriate approach, there is a tradeoff between choosing shorter vs. longer landmark times. When a longer landmark time was used, the number of patients excluded from the analysis for death or being censored before the selected landmark time increases. This could affect the statistical power of the analysis and the generalizability of the results. It is not surprising that CIs are slightly wider than those in ManteleByar analysis. Also, when large immediate effects (benefit or adverse effects) from the treatment were expected, estimates from the landmark method will provide an incomplete picture of the effectiveness of the treatment. Nonetheless, SCD-HeFT showed that the benefit of ICD therapy was only observed 1.5 years after implantation (i.e., delayed effect) [19] . Therefore, events occurring within 120 days following the index discharge were unlikely to be related to the therapy. In our example assessing the effectiveness of ICDs, the landmark method provided not only a valid but also a clinically meaningful approach to assessing the effectiveness of the therapy owing to the expected delayed effect. Researchers should assess whether the landmark method could provide meaningful estimates for their study question and choose an appropriate landmark time based on the natural time of clinical significance (i.e., the end of induction therapy in patients with cancer) before the data analysis [8] and consider multiple landmark times in sensitivity analyses. As expected, the exclusion method yielded the smallest hazard ratios and approximately 16% bias in favor of treatment. This method estimates the hazard correctly in the ICD group but overestimates the hazard in the non-ICD group because the immortal time is excluded from the denominator of the hazard calculation for the non-ICD group. As a result, the hazard ratio of treatment is always underestimated. The magnitude of this bias depends on the proportion of the excluded immortal time. The more excluded immortal time, the larger the bias, which was shown in a simulation study [29] .
As expected, the time scale affected the results only when all person-time was accounted for and appropriately classified using the ManteleByar method. Contrary to our expectation that time on disease might be the most appropriate time scale in the study, using time on study yielded a larger hazard ratio (0.83 vs. 0.78) than using first hospitalization or date of birth. Although disease duration is likely to affect the outcome, and the timing of device use is likely to be associated with disease duration, we probably did not capture the true scale for disease duration using our surrogate measure, which was the time from the first hospitalization.
Our study has limitations. First, the true effect of ICD therapy in the study population is unknown. As a consequence, we relied on trial data and existing evidence to derive an expected effect in this population and estimated the relative amount of bias compared with the reference ManteleByar method. Currently, an extensive simulation study is being conducted to determine the magnitude of bias introduced as the risk for exposure varies over time. Second, we did not adjust for registry variables or have access to outpatient and pharmacy data for estimating the hd-PS. Therefore, the extent of residual confounding may be larger, and direct comparison between the hazard ratios from the major trials and our estimates may be inappropriate. Third, the choice of the landmark time cannot be generalized and should be based on the natural time of clinical significance. Exclusion of patients who died before the landmark time may affect statistical efficiency and precision.
Immortal time bias is well recognized and described in the epidemiology and pharmacoepidemiology literature 
